Edition:
India

Biomerica Inc (BMRA.OQ)

BMRA.OQ on NASDAQ Stock Exchange Capital Market

6.55USD
2:29am IST
Change (% chg)

$-0.40 (-5.76%)
Prev Close
$6.95
Open
$7.02
Day's High
$7.02
Day's Low
$6.51
Volume
27,285
Avg. Vol
66,406
52-wk High
$23.38
52-wk Low
$2.05

Summary

Name Age Since Current Position

Zackary Irani

54 1997 Chairman of the Board, Chief Executive Officer

Allen Barbieri

62 2020 Lead Independent Executive Vice Chairman of the Board

Steven Sloan

50 2020 Chief Financial Officer

Janet Moore

68 2020 Treasurer, Secretary, Director

Francis Cano

76 1999 Independent Director

Catherine Coste

54 2020 Independent Director

Jane Emerson

66 2007 Independent Director

Mark Sirgo

66 2016 Independent Director

Biographies

Name Description

Zackary Irani

Mr. Zackary S. Irani serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Zackary Irani has been a Director of the Company, and has been serving as the Company's Chairman of the Board and Chief Executive Officer since April 29, 1997. Prior to that time, Mr. Irani served as the Company's Vice President of Business Development. He has been an employee of the Company since 1986. During fiscal 2008 and 2009, Mr. Irani also served as Chairman of the Board of Lancer Orthodontics, Inc. and served as Lancer's Chief Executive Officer from April 1997 until April 2004.

Allen Barbieri

Mr. Allen C. Barbieri serves as Lead Independent Executive Vice Chairman of the Board of the Company. Mr. Barbieri is currently a private investor. From January 2010 to March 2018 Mr. Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as major investors. Prior to that, from April 2004 to September 2009, Mr. Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical products company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer and from 1994 to 1999 Mr. Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Barbieri also currently serves as a member of the board of directors of CareTrust REIT, Inc.

Steven Sloan

Mr. Steven Sloan serves as Chief Financial Officer of the Company. Mr. Sloan's background and experience includes thirteen years at General Electric with roles in internal audit, corporate finance and manufacturing finance. Most recently, Mr. Sloan spent ten years with medical device maker, Medtronic. At Medtronic, Mr. Sloan worked in four divisions, most recently serving as a divisional finance director.

Janet Moore

Ms. Janet Moore is no longer serves as Treasurer, Secretary, Director of the Company effective 12/10/2020. Ms. Janet Moore has been a Director of the Company since April 29, 1997, and has been serving as the Company's Secretary and Treasurer since 1985. She has served as the Company's Chief Financial Officer since 1999 and has been an employee of the Company since 1976. From fiscal 1998 through 2008, Ms. Moore also served as a director and Secretary of Lancer Orthodontics, Inc.

Francis Cano

Dr. Francis R. Cano Ph.D. serves as Independent Director of the Company. Dr. Cano is the managing director of Cano Biotechnology, a consulting business which is focused on vaccines and immunotherapeutics. He co-founded Aviron in 1993 and served as the President and Chief Operating Officer. The Company developed the intranasal flu vaccine, Flu-Mist, and was acquired by MedImmune in 2002 for $1.2 billion. From 1972-1993 Dr. Cano held various scientific/management positions with American Cyanamid, the last of which was as Vice President-General Manager of the Lederle-Praxis Biological Division. From fiscal 2001 through 2008, Dr. Cano also served on the board of Lancer Orthodontics, Inc., and currently serves on the board of Arbor Vita Corporation and Dynavax.

Catherine Coste

Ms. Catherine Coste CPA serves as Independent Director of the Company. Ms. Coste recently retired from Deloitte and Touche, where she was a senior partner and served as Deloitte’s Life Sciences Industry Executive Leader. She spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Coste also has extensive public company Board experience, often attending multiple Board Committee meetings per month. Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls and corporate governance. Ms. Coste is a Certified Public Accountant.

Jane Emerson

Dr. Jane F. Emerson M.D. Ph.D. serves as Independent Director of the Company. Since July 1, 2009, Dr. Emerson has served as Vice Chair for Clinical Programs and Chief of Clinical Pathology at the University of Southern California Keck School of Medicine, Los Angeles, California. From 1994 to 2009, Dr. Emerson was on the faculty of the University of California, Irvine School of Medicines where she served as Chief of Clinical Pathology and from 2000 to 2009, also served as the Vice Chair for Clinical Programs, Department of Pathology and Laboratory Medicine.

Mark Sirgo

Dr. Mark A. Sirgo Ph.D. serves as Independent Director of the Company. He previously served as President & CEO of BioDelivery Sciences International, Inc. (“BDSI”) from January 2005 until January of 2018. He joined BDSI in August 2004 as Senior Vice President of Commercialization and Corporate Development upon the acquisition of Arius Pharmaceuticals, of which he was a co-founder and Chief Executive Officer. While at BDSI he oversaw the FDA approval and commercialization of three products for pain and addiction medicine. Dr. Sirgo has over 30 years of experience in the pharmaceutical industry, including 16 years in clinical drug development, 7 years in marketing, sales, and business development and 15 years in executive management positions. Prior to his involvement with Arius Pharmaceuticals, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc., a leading contract service provider to the pharmaceutical industry.

Basic Compensation

Name Fiscal Year Total

Zackary Irani

330,481

Allen Barbieri

--

Steven Sloan

--

Janet Moore

155,643

Francis Cano

--

Catherine Coste

--

Jane Emerson

--

Mark Sirgo

--
As Of  31 May 2020

Options Compensation